Jordyn Sava

The MARIPOSA study seeks to assess efficacy, safety, and pharmacokinetics of the combination of amivantamab-vmjw and lazertinib in locally advanced, or metastatic non-small cell lung cancer.

In an interview with Targeted Oncology, Annelise Wilhite, MD, discussed the findings of a clinical investigation of survival in patients with vulvar/vaginal melanomas.

The FDA has approved FoundationOne CDx as a companion diagnostic to pembrolizumab for patients with microsatellite instability high solid tumors.

In an interview with Targeted Oncology, Tanios S. Bekaii-Saab, MD, explained how adagrasib works to target KRAS mutations as well as its importance.

BOS172738 shows promising results in the treatment of RET gene altered medullary thyroid cancer and non–small cell lung cancer, according to a phase 1 study.

In an interview with Targeted Oncology, Vitaly Margulis, MD, discussed the function and findings of metabolomics in renal cell carcinoma.

Srdan Verstovsek, MD, discussed maintaining hematocrit levels in patients with polycythemia vera as well as research on the use of rusfertide.

A phase 2 trial sought to evaluate the efficacy and safety of the combination of anlotinib and sintilimab in patients with recurrent advanced endometrial cancer.

The FDA has accepted a new drug application for adagrasib for the treatment of patients with non-small cell lung cancer harboring KRAS G12C mutation.

In an interview with Targeted Oncology, Bridget Koontz, MD, United States chief medical officer and deputy global chief medical officer at GenesisCare, discusses 18F-DCFPyL and how the well-tolerated agent can change the way prostate cancer patients are treated

CT103A is a BCMA-targeted genetically modified autologous T cell immunotherapy that is able to identify and eliminate malignant and normal cells expressing BCMA in R/R Myeloma.

Treatment with multiple nucleic acid immunotherapy agents is being evaluated in phase 1/2 clinical trials.

An application for FDA approval has been submitted for poziotinib as a potential treatment for patients with non–small cell lung cancer harboring HER2 exon 20 insertion mutations.

In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.

In KEYNOTE-522, treatment with adjuvant pembrolizumab following neoadjuvant pembrolizumab with chemotherapy showed a statistically significant prolonged event-free survival in patients with high-risk early-stage triple-negative breast cancer.

In an interview with Targeted Oncology, James Brugarolas, MD, PhD discussed promising updated survival data in metastatic renal cell carcinoma and investigational biomarkers to further advanced the field.

The novel oncolytic adenovirus, VCN-01 has been granted FDA orphan drug designation for retinoblastoma and will soon be investigated in a phase 2/3 clinical trial.

Acute myeloid leukemia has one of the highest unmet needs for new therapies out of all human cancers, according to Marcin Kortylewski.

Umbralisib is potentially linked to an increased risk of death in patients with lymphomas, according to an alert for clinical and patients announced by the FDA.

Based on data from phase 3 ECHELON-1 brentuximab vedotin in combination with chemotherapy extends survival in patients with advanced classical Hodgkin lymphoma.

In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.

In an interview with Targeted Oncology, Yelena Ginzburg, MD, discussed the research and use of rusfertide in patients with polycythemia vera.